SCHEMBL4251187

SCHEMBL4251187

COC(=O)c1cccc2c1ncn2Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.50
EGLN3 Q9H6Z9 1/20 0.49
YTHDC1 Q96MU7 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
TNF P01375 1/20 0.48
CYP11B1 P15538 1/20 0.48
CYP11B2 P19099 1/20 0.48
NR1H4 Q96RI1 5/20 0.47
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
P2RX7 Q99572 1/20 0.45
PKM P14618 1/20 0.44
LMNA P02545 1/20 0.44
IDO1 P14902 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28398222 0.89 L3MBTL1 (0.50) YTHDC1L3MBTL1CYP11B1CYP11B2NR1H4
SCHEMBL23293667 0.85 CYP11B1 (0.54) EGLN1EGLN3TNFCYP11B1CYP11B2
SCHEMBL12894984 0.84 NR4A2 (0.52) EGLN1YTHDC1L3MBTL1LMNA
SCHEMBL1081805 0.80 EGLN1 (0.69) EGLN1EGLN3TNFCYP11B1CYP11B2
SCHEMBL28440773 0.80 CYP11B1 (0.48) L3MBTL1TNFCYP11B1CYP11B2P2RX7
SCHEMBL28634932 0.80 CYP17A1 (0.48) EGLN1NR1H4LMNA
SCHEMBL1080421 0.79 EGLN3 (0.55) EGLN1EGLN3YTHDC1L3MBTL1NR1H4
SCHEMBL1082082 0.79 EGLN3 (0.52) EGLN1EGLN3YTHDC1L3MBTL1NR1H4
SCHEMBL18038344 0.79 KDM4E (0.43) EGLN1L3MBTL1LMNA
SCHEMBL27801091 0.78 LCK (0.42) EGLN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234220-B2 Immunomodulatory compounds DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-02-25 US disclosed
US-20210284624-A1 IMMUNOMODULATORY COMPOUNDS DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-09-16 US disclosed
US-20210284624-A1 IMMUNOMODULATORY COMPOUNDS DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-09-16 US disclosed
CN-113166100-A Immunomodulatory compounds 达纳-法伯癌症研究所有限公司 2021-07-23 CN disclosed
EP-3814330-A1 IMMUNOMODULATORY COMPOUNDS Dana-Farber Cancer Institute, Inc. (US) 2021-05-05 EP disclosed
WO-2009134850-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210284624-A1 IMMUNOMODULATORY COMPOUNDS CRBN, CD47, CD58 EGLN1 2345/4885EGLN3 3226/4885YTHDC1 4525/4885
US-12234220-B2 Immunomodulatory compounds CRBN, CD47, CD58 EGLN1 2345/4885EGLN3 3226/4885YTHDC1 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.